ArticleOncotarget2016

MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.

Jingjin Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.